

# 2019 Nuggets in Infectious Diseases for the Hospital-Based Practitioner

Sarah S. Long, M.D.

Professor of Pediatrics Drexel University College of Medicine Section of Infectious Diseases St. Christopher's Hospital for Children Philadelphia, Pennsylvania





Disclosure: Dr. Long is an associate editor of the Red Book 2018-2021 and The Journal of Pediatrics



A 6-month-old infant is hospitalized because of a prolonged febrile seizure.

PCR assay performed on nasopharyngeal specimen is positive for rhinovirus.

Rhinovirus

A. Is likely to be the cause of the problemB. Is unlikely to be the cause of the problemC. May or may not be the cause of the problem



Community Surveillance of Respiratory Viruses Among Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study Clinical Infectious Diseases<sup>®</sup> 2015;61(8):1217-24

Carrie L. Byington,<sup>1,s</sup> Krow Ampofo,<sup>1,s</sup> Chris Stockmann,<sup>1</sup> Frederick R. Adler,<sup>2,3</sup> Amy Herbener,<sup>1</sup> Trent Miller, Xiaoming Sheng,<sup>1</sup> Anne J. Blaschke,<sup>1</sup> Robert Crisp,<sup>4</sup> and Andrew T. Pavia<sup>1</sup>

Viral respiratory illnesses common and have a broad range of symptoms PCR testing  $\uparrow$  sensitivity to detect. How to interpret ?

#### **Methods**


Prospective family study for 1 yr taking weekly diaries and nasal s Viral illness defined as <u>></u>1 consecutive wks same virus + <u>></u> 1wks syr


## Findings

Utah 26 households, 108 individuals, 4166 person-weeks Participants reported symptoms ~25% person-weeks Virus detected ~25% person-weeks Age <5 years ~2x more symptoms and ~4x more virus detection (5 Individual living w children had 3 add'l weeks virus detection/year Symptoms in ~50% virus detections (CoV, hMPV, Inf) Asymptomatic virus detections (Boca & Rhino) Mean duration PCR detection/virus 1.7 weeks (long tails) Young children had longer shedding





# **Bottom line: Children ARE little virus factories !!!!**





Age matters to the child Presence of children matters to the household Long Tails







Your 14-year-old fully immunized patient has had a URI, followed by a hacking non-productive cough that is not improving after one week. Blowing his nose is productive of thick yellow-green secretions. Physical examination is normal.

You consider the differential diagnosis and obtain a nasal swab specimen for a newly marketed multiplex PCR assay.

# Here are the results:

#### **Pediatric Respiratory**

- Adenovirus types 3, 4, 7, 21 Enterovirus group Human bocavirus Human coronavirus (4 types) Human metapneumovirus Influenza A - Human influenza Influenza A - H1N1-09 Influenza B Parainfluenza virus types 1, 2, 3, 4 Respiratory Syncytial Virus (A & B) Rhinovirus
- Bordetella pertussis
   Chlamydophila pneumoniae
   Haemophilus influenzae
   Haemophilus influenzae (Type B)
   Moraxella catarrhalis
   Mycoplasma pneumoniae
   Neisseria meningitidis
   Streptococcus dysgalactiae (Group C, G)
   X Streptococcus pneumoniae
   Streptococcus pyogenes (Group A)

# The positive test:

- A. suggests that he has pneumococcal sinusitis
- **B.** suggests that he is a PCV13 failure, and may have an immunologic problem
- C. means absolutely nothing



Your 14-year-old fully immunized patient has had a URI, followed by a hacking non-productive cough that is not improving after one week. Blowing his nose is productive of thick yellow-green secretions. Physical examination is normal.

You consider the differential diagnosis and obtain a nasal swab specimen for a newly marketed multiplex PCR assay.

# Here are the results:

#### **Pediatric Respiratory**

- Adenovirus types 3, 4, 7, 21 Enterovirus group Human bocavirus Human coronavirus (4 types) Human metapneumovirus Influenza A - Human influenza Influenza A - H1N1-09 Influenza B Parainfluenza virus types 1, 2, 3, 4 Respiratory Syncytial Virus (A & B) Rhinovirus
- Bordetella pertussis
   Chlamydophila pneumoniae
   Haemophilus influenzae
   Haemophilus influenzae (Type B)
   Moraxella catarrhalis
   Mycoplasma pneumoniae
   Neisseria meningitidis
   Streptococcus dysgalactiae (Group C, G)
   Streptococcus pneumoniae
   Streptococcus pyogenes (Group A)

## A confirment het he heer

The positive test:

- A. confirms that he has pertussis
- **B.** suggests that he is an asymptomatic carrier because he had Tdap
- **C.** Means absolutely nothing



Your 14-year-old fully immunized patient has had a URI, followed by a hacking non-productive cough that is not improving after one week. Blowing his nose is productive of thick yellow-green secretions. Physical examination is normal.

You consider the differential diagnosis and obtain a nasal swab specimen for a newly marketed multiplex PCR assay.

## Here are the results: Pediatric Respiratory

- Adenovirus types 3, 4, 7, 21 Enterovirus group Human bocavirus Human coronavirus (4 types) Human metapneumovirus Influenza A - Human influenza Influenza A - H1N1-09 Influenza B Parainfluenza virus types 1, 2, 3, 4 Respiratory Syncytial Virus (A & B) Rhinovirus
- Bordetella pertussis Chlamydophila pneumoniae Haemophilus influenzae Haemophilus influenzae (Type B) Moraxella catarrhalis Mycoplasma pneumoniae
- Neisseria meningitidis Streptococcus dysgalactiae (Group C, G) Streptococcus pneumoniae Streptococcus pyogenes (Group A)
- A. warrants prescribing azithromycin

The positive test:

- B. does not warrant prescribing azithromycin
- **C.** has no bearing on a prescribing decision

## **CNS Human Parechovirus – Kansas City**

StudyRetro 388 CSF specimens from children < 18 yrs</th>who had EV testing performed, 2009RT-PCR → HPeV+All were < 6 mo</td>Compared clinical of all patients tested < 6 mo age</td>

Results	<u>HPeV+ (66)</u>	<u>EV+ (47)</u>	<u>Negative (66)</u>
Age (d)	41	31	43
PICU	12%	2%	0
T max	>39	38.4	38
Days fever	2.7	2	1.6
CSF WBC	2%	38%	12%
Periph WBCs	5.8	9.2	10.1


HPeV3 is an emerging CNS pathogen & should be considered in young infants w or w/o CSF <u>pleocytosis</u>

# **CNS Human Parechovirus – Los Angeles**

**Study** Retro 440 CSF specimens from children who had evaluation for infection Compared <u>HPeV+ vs</u> EV+

Results	<u>HPeV+ (12)</u>	<u>EV+ (43)</u>
Age < 6 <u>mo</u>	67%	67%
Seizures	42%	14%
CNS S/S	75%	30%
URI	<b>58%</b>	16%
Vomiting	25%	26%
CSF WBCs	(25%)	82%

#### HPeV is a CNS pathogen and should be considered




ARTICLES

#### **Case series 32 perinatally acquired HSV infections**

- 50% had only nonspecific S/S at presentation which was fever in 75%
- 75% had CNS HSV

CNS HSV was confirmed in 40% cases with clin mucocutan only, 83% with seizures, 94% HSV with nonspecific S/S only

Age ≤ 21 days at onset S/S captured 90% of all cases and 94% with nonspecific S/S only



#### Shah. Pediatr 2011;128:1153

Delayed Acyclovir Therapy and Death Among Neonates With Herpes Simplex Virus Infection Delay acyclovir Rx perinatal HSV from Hosp Day 1 to Day 2/3 was assoc with 个OR death 2.63







# Don't forget to look


www.jpeds.com • The Journal of Pediatrics

ORIGINAL ARTICLES

2012;161:134

#### Neonatal Herpes Disease following Maternal Antenatal Antiviral Suppressive Therapy: A Multicenter Case Series

Swetha G. Pinninti, MD<sup>1</sup>, Radhika Angara, MD<sup>2</sup>, Kristina N. Feja, MD, MPH<sup>3,4</sup>, David W. Kimberlin, MD<sup>1</sup>, Charles T. Leach, MD<sup>5</sup>, Dennis A. Conrad, MD<sup>5</sup>, Carol A. McCarthy, MD<sup>6</sup>, and Robert W. Tolan, Jr., MD<sup>3,7</sup>





Accuracy of Herpes Simplex Virus Polymerase Chain Reaction Testing of the Blood for Central Nervous System Herpes Simplex Virus Infections in Infants JPediatr 2018;200:274

Todd W. Lyons, MD, MPH<sup>1</sup>, Andrea T. Cruz, MD, MPH<sup>2</sup>, Stephen B. Freedman, MDCM, MSc<sup>3</sup>, and Lise E. Nigrovic, MD, MPH<sup>1</sup>, for the Herpes Simplex Virus Study Group of the Pediatric Emergency Medicine Collaborative Research Committee (PEMCRC)

23 Emergency Dept evaluations of infants < 60 days with CSF and blood PCR for HSV</td>Infants had both tests performed1038Infants had CSF HSV+21/1038 (2%)Infants had CNS HSV and blood PCR+16/21 (76%)

☑ Positive blood PCR does not change HSV category from mucocutaneous to dissem

- ✓ CSF PCR is a great test for CNS HSV
- ☑ Blood is frequently but not always PCR+ with CNS HSV infection
- ☑ Negative blood PCR does not exclude CNS HSV



# The Prevalence of Neonatal Herpes Simplex Virus Infection Compared with Serious Bacterial Illness in Hospitalized Neonates

A. CHANTAL CAVINESS, MD, PHD, GAIL J. DEMMLER, MD, YVETTE ALMENDAREZ, MD, AND B.J. SELWYN, SCD

All hosp Fever	<u>No</u> 5817 960	<u>SBI</u> 4.6% 14.2%	<u>Virus</u> 8.4% 17. <del>2%</del> 0.3% HSV
		<u>Bact men</u>	<u>HSV</u>
CSF pleo	204	5.4%	1.0%
CSF poly pleo	80	14.9%	
CSF mono pleo	124	0.8%	1.6%
Age 8-14 days	1400	0.2%	0.6%
Hypothermia	187		1.1%



Aronson et al

Variation in Care of the Febrile Young Infant  ${<}90\,\mathrm{Days}$  in US Pediatric Emergency Departments

The StudyRetrospective cohort study febrile infants < 90 days age<br/>US PHIS administrative database<br/>37 Pediatric Hospital EDs 7/1/2011 – 6/30/2013<br/>Variation testing, treatment, re-visitsThe Findings35,000 ED visits for fever without focus

Large inter-hospital variation management

Little inter-hospital variation outcome

Blood + urine + CSF test Hospitalized Hospitalized no IV/IM Abx Hospitalized + acyclovir Discharged ED Discharged no IV/IM Abx SBI

	<u>&lt;</u> 28d	29-56d	57-89d	_
/	72%	49%	13%	_
	78%	44%	16%	
	4%	<b>12%</b>	27%	
	32%	<b>12%</b>	5%	
	22%	66%	84%	
	<b>96%</b>	<b>79%</b>	86%	
	11%	8%	8%	



#### Using Multiplex Molecular Testing to Determine the Etiology of Acute Gastroenteritis in Children J Pediatr 2016; 176:50

Maribeth R. Nicholson, MD, MPH<sup>1</sup>, Gerald T. Van Horn, PhD<sup>2</sup>, Yi-Wei Tang, MD, PhD<sup>3</sup>, Jan Vinjé, PhD<sup>4</sup>, Daniel C. Payne, PhD<sup>4</sup>, Kathryn M. Edwards, MD<sup>5</sup>, and James D. Chappell, MD, PhD<sup>6</sup>

#### What We Knew

Episodes acute gastroenteritis (AGE) total 5 billion worldwide annually AGE causes 15%-30% of all chhildhood deaths in some countries In US, routine lab tests  $\rightarrow$  etiologic agents in only 60% of outbreaks  $\leq 30\%$  sporadic cases


#### The Study

Prospective pop-based surveillance study in TN children <6 yrs Cases: 216 with AGE versus 36 controls Multiplex PCR + rRT-PCR

#### The Findings

>1 pathogen in 70% AGE versus 11% controls

PCR too sensitive for *C. difficile*? PCR<sup>+</sup> 8% controls 0-51 mos 14% controls <12 mos






A 17-month-old toddler has fever and refuses to bear weight on the right leg. Examination reveals swelling, tenderness and decreased range of motion of the knee. He previously was well, attends daycare and is fully immunized. Mother is a pediatric nurse. Culture of knee aspirate yields S.pneumoniae.

# You should consider this infection as


- A. Due to bad luck
- **B.** Likely acquired through daycare exposures
- **C.** Possibly related to mother's work exposures
- **D.** Possibly indicative of an immune defect

# Direct effects of PCV7: Rates of IPD in children <5 years, 1998/99-2006

--- Overall --- PCV7 type




# Direct and indirect effects of PCV7 on IPD by age group in the U.S., 2006




Age group (years)

\*Difference in estimated number of cases in 2006 and 1998/99

#### **Impact of PCV13 on Invasive Pneumococcal Disease, Denmark**





Harboe ZB et al. CID 2014;59:1066

# **At Risk Populations**


 $\diamond$  Prior to PCVs, healthy children represented majority of IPD cases

♦ By 2013, 45% (160/352) of children with IPD had chronic underlying conditions

Underlying Condition	% of patients (N=160)
Malignancy	27%
Genetic	11%
Cardiovascular	9%
Renal	8%
Central Nervous System	6%
HIV/Hemoglobinopathy/ Asplenia	3% each
Other	55%



IPD Increasingly affects children with underlying conditions, has less clustering of serotypes and around influenza seasons. Vodzak J, Evangelista AT, Gould JM, Long SS. IDSA, Vancouver, Oct, 2010



Kaplan S, et al Oral Abstract IDSA 2014



2014;59:244

Invasive Pneumococcal Disease in Children Can Reveal a Primary Immunodeficiency

Jean Gaschignard,<sup>1,2,3</sup> Corinne Levy,<sup>3,4,5</sup> Maya Chrabieh,<sup>1,2</sup> Bertrand Boisson,<sup>6</sup> Cécile Bost-Bru,<sup>7</sup> Stéphane Dauger,<sup>8</sup>

# **Methods:** Prospective study of children with IPD in 28 hospitals in France in PCV-era (2005-2011)

- Immunologic assessment
  - CBC with smear, abdominal ultrasound, immunoglobulin & complement levels, proinflammatory cytokines

## **Results:** 163 children Primary Immunodeficiency: 10%

Age range: 2mo-9 yrs Most common infection: Meningitis Both vaccine & non-vaccine serotypes Antibody deficiency Innate immunity deficiency Transient immunoglobulin deficiency

Systematic immunologic evaluation for all children hospitalized with IPD

# **Bottom Line**

- ☑ Incidence of invasive pneumococcal disease is continuing to decline in post-PCV13 era without evidence of serotype replacement
- Serotyping should be performed on pneumococcal isolates from all patients with IPD

#### **IPD cases in children in 2019**



have known chronic medical conditions



Subspecialty consultation

**☑** Systematic immunologic evaluation



**D.** Possibly indicative of an immune defect

Rotavirus Facts	<ul> <li>Rotavirus was the leading cause of AGE in &lt;5 year olds</li> <li>Risk hosp RV ↑ if premature, daycare, Medicaid, another child (Dennehy.PIDJ 2006)</li> <li>RV1 (Rotarix) in 2006 and RV5 (RotaTeq) in 2008 → dramatic ↓ RV/AGE by direct and indirect effect</li> <li>RV5 is safe/effective in premature infants w dose 1 @ 6–12 wks (Goveia. PIDJ 2007)</li> <li>Premature infants excrete vRV5 post dose 1 thru-out 14 days 53% antigen+/87% PCR+ (Smith.Vaccine 2011)</li> <li>Age-limited rec for term/preterm for dose1 @ 6 – 14<sup>6/7</sup> wks</li> <li>8% U.S. births are preterm/LBW (&lt;2500 g) 1.4% U.S. births are VLBW(&lt;1000g)</li> <li>25% LBW infants age out of vRV eligibility in hospital</li> </ul>	A Acute gastro 700 - 650 - 550 - 550 - 550 - 550 - 450 - 450 - 100 400 - 350 - 200 - 200 - 200 200	Normal Birth Weight Low Birth Weight Very Low Birth Weight Very Low Birth Weight 4 2005 2006 2007 2008 2009 2010 2011 20 12 2013 2014 2015 2006
	Effect of Rotavirus Vaccination on Acute Diarrheal Hospitalizations Among Low and Very Low Birth Weight US Infants, 2001–2015 PIDJ 2018;37:817 becca M. Dahl, MPH,* Aaron T. Curns, MPH,† Jacqueline E. Tate, PhD,† and Umesh D. Parashar; MBBS, MPH†		B Rotavirus-coded hospitalizations
Study Findings	Insurance claims hospitalization AGE/Rota @ $\leq 5$ yrs and receipt of RV Birth weight: Normal v LBW v VLBW Vaccine coverage: 87% v 82% v 64% (22% of VLBW got dose 1 out of Rota hosp $\downarrow$ all: 98% v 93% LBW & VLBW		000000 - 1200 - 120 -
Conclude	Rotavirus vaccines are highly effective. Should continue to ↑efforts to immunize LBW and VLBW.		40 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

# What is the risk of vRV in the NICU, given on schedule?

LDI	TRICS
	Control Contro
	And a constraint of the second

 Safety of rotavirus vaccine in the NICU.
 Characteristics

 Pediatrics 2014;133:e1555
 State

 Monk HM<sup>1</sup>, Motsney AJ<sup>2</sup>, Wade KC<sup>3</sup>.
 State

Experiential



Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. Vaccine 2015;33:5095

Thrall S<sup>1</sup>, Doll MK<sup>2</sup>, Nhan C<sup>1</sup>, Gonzales M<sup>1</sup>, Perreault T<sup>3</sup>, Lamer Particulation of the second second



Risk of Rotavirus Nosocomial Spread After Inpatient PentavalentRotavirus Vaccination.Pediatrics 2018;141:1

<u>Hofstetter AM</u><sup>1,2</sup>, <u>Lacombe K</u><sup>2</sup>, <u>Klein EJ</u><sup>3,2</sup>, <u>Jones C</u><sup>2</sup>, <u>Strelitz B</u><sup>2</sup>, <u>Jacobson E</u><sup>3,2</sup>, <u>Ranade D</u><sup>2</sup>, <u>Ward ML</u><sup>4</sup>, <u>Mijatovic-Rustempasic S</u><sup>4</sup>, <u>Evans D</u><sup>4</sup>, <u>Wikswo M</u><sup>4</sup>, <u>Bowen MD</u><sup>4</sup>, <u>Parashar UD</u><sup>4</sup>, <u>Payne DC</u><sup>4</sup>, <u>Englund JA</u><sup>3,2</sup>.

CHOP: Policy routine RV5 in NICU@ 2m in enteral feeds Standard precautions 89 infants RV5 dose 1 in NICU/801 pod mates 7-day screening window vaccinees/14-day pod mates Clinical changes post RV5 24% vaccines/2% pod mates Thought not related (2 PCR tests: neg)

Canada: Similar policy and study method 102 infants RV5 dose 1 in NICU No clinical changes in vaccinees No nosocomial rotavirus disease recognized

#### Active NICU/PICU surveillance

≥37 wks postmenstrual age + <15wks postnatal age During CDC study: hospital wkly stool PCR rotavirus Defined potential exposure & geotemporal proximetry 755 infants →335 enrolled →33 pts RV5 dose 1 (<19 NICU) No vRV5 except in vaccinees (IR 0/1000 pt days risk) What More We Know about vRVs

- ✓ Currently there is substantial community (herd) protection from RVs. No U.S. deaths
- ✓ RV5 is effective in premature infants
- ✓ Excretion of vRV5 in premature is > term infant
- ✓ Small experiences in NICUs with mature infection control → little transmission
- ✓ Wild rotavirus in 1° Immunodeficiency → prolonged diarrhea, excretion, antigen in serum (Saulsbury JPediatr 1980)

#### <u>Reasons for Age-Limited Recommendation vRVs</u>

- ✓ Large safety studies dose 1 only in age 6-14<sup>6/7</sup> weeks
- ✓ 1)Expect some matAb 2) Timing@age before ↑spont intussusception =

#### What We Still Need to Know about vRVs

- ✓ Efficacy of vRVs in ELBW infants
- ✓ Safety of vRVs in immunized ELBW infants themselves
- ✓ Generalizable risk of NICU transmission of vRVs pt-to-pt
- ✓ Risk of vRV disease/transmission after contact acquisition

Rotavirus Vaccines, Preterm Infants and Nurseries

 Preterm infants should be immunized on the same schedule [with age limits] as recommended for full-term.

2018

Red

BOOK®

 When the preterm infant is eligible, dose 1 of vaccine should be administered at the time of/or after the infant's discharge from the nursery.